 |
인쇄하기
취소
|
Janssen Korea to market Remicade
Published: 2011-07-01 06:59:00
Updated: 2011-07-01 06:59:00
Starting in July 1, Janssen Korea will have a marketing right for Remicade as a high-stake fight between Merck and Johnson & Johnson over the rights to a pair of lucrative arthritis medicines - Remicade and Simponi - was finally resolved in April.
Under the deal, Merck will relinquish exclusive marketing rights to the drugs in various locales: Canada, Central and South America, the Middle Ea...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.